Call 24/7:


Ibogaine Addiction

pexels jonathan borba 2888492

Ibogaine Addiction

Ibogaine Treatment for METHADONE, KREATOM, addiction



GENDER: MALE        




Treatment Duration and Dosage

The ibogaine treatment spanned 8 days, with varying dosages administered each day, ranging from 125 mg to 250 mg.  This blood report presents the before-and-after results of a patient who underwent an 8-day ibogaine treatment. Several health parameters were assessed to evaluate the impact of the treatment.


1- Blood Pressure

The patient’s blood pressure readings showed significant variation during the treatment. Initially, it was at 142/96, then gradually decreased to 129/75 after almost a week. This indicates that ibogaine treatment may have contributed to blood pressure regulation, resulting in an overall positive outcome.

2- Heart Rate

The patient’s heart rate exhibited fluctuations throughout the treatment. It started at 72 beats per minute (bpm), increased to 90 bpm on the second day, but eventually stabilized at 69 bpm on the following days. While there were fluctuations, the heart rate remained within a normal range.

3- Glucose Levels

The patient’s glucose levels showed variations during the treatment. The levels were within the normal range on most days. However, on the fourth day, the glucose level peaked at 136 mg/dL, which might be a concern. Overall, further monitoring may be needed to understand the long-term impact on glucose control.

4- SATO2

Oxygen saturation levels remained relatively stable, indicating that the patient maintained sufficient oxygen levels in their blood throughout the treatment.

5- Cell Blood Count

The cell blood count revealed improvements in some parameters. Lymphocyte counts decreased from 24 to 16, and eosinophil counts remained stable. Neutrophil counts increased from 72 to 80.

6- Biochemistry

The biochemistry panel showed changes in several parameters. Uric nitrogen, urea in serum, and uric acid levels increased post-treatment, indicating potential effects on kidney function. creatinine levels decreased, suggesting a reduction in the risk of gout. Importantly, the patient’s methadone, kratom, and tianna usage may have influenced these results.

7- Lipid Profile

The lipid profile displayed variations, with total cholesterol levels decreasing slightly from 191.0 mg/dL to 189.0 mg/dL and LDL cholesterol levels increasing from 127.7 mg/dL to 144.5 mg/dL. HDL cholesterol levels also increased, indicating potential effects on lipid metabolism.

8- Liver Function

Liver function markers, including AST, ALT, total bilirubin, indirect bilirubin, direct bilirubin, LDH, and GGT, remained within normal ranges post-treatment, suggesting that ibogaine treatment did not negatively impact liver function.

9- A1C Hemoglobin and C-Reactive Protein

A1C hemoglobin levels increased from 4.5% to 5.9% post-treatment, indicating changes in long-term glucose control. C-reactive protein (CRP) levels also increased very slightly, indicating a slight increase in inflammation.

10- Hormone Levels

Total testosterone levels decreased significantly from 22.09 ng/mL to 3.26 ng/mL, which is a notable change.

11- Thyroid Function

Thyroid function markers TSH and Free T4 displayed variations, with TSH and Free T4 increasing post-treatment. These changes may require further evaluation to assess their clinical significance.

12- Urine Drug Test

The urine drug test showed a positive result for benzodiazepines (BZD) post-treatment, suggesting a change in drug usage patterns.



The blood report on ibogaine treatment reveals varied impacts: potential blood pressure benefits, kidney concerns, and fluctuations in glucose, lipids, and hormones. Notably, total testosterone levels decreased significantly. Monitoring drug usage is crucial, as indicated by the positive BZD result. A comprehensive understanding of long-term effects necessitates further research and medical supervision.




Accessibility Toolbar